Clinical outcomes of asleep vs awake deep brain stimulation for Parkinson disease

Objective: To compare motor and nonmotor outcomes at 6 months of asleep deep brain stimulation (DBS) for Parkinson disease (PD) using intraoperative imaging guidance to confirm electrode placement vs awake DBS using microelectrode recording to confirm electrode placement. Methods: DBS candidates with PD referred to Oregon Health & Science University underwent asleep DBS with imaging guidance. Six-month outcomes were compared to those of patients who previously underwent awake DBS by the same surgeon and center. Assessments included an “off”-levodopa Unified Parkinson’s Disease Rating Scale (UPDRS) II and III, the 39-item Parkinson's Disease Questionnaire, motor diaries, and speech fluency. Results: Thirty participants underwent asleep DBS and 39 underwent awake DBS. No difference was observed in improvement of UPDRS III (+14.8 ± 8.9 vs +17.6 ± 12.3 points, p = 0.19) or UPDRS II (+9.3 ± 2.7 vs +7.4 ± 5.8 points, p = 0.16). Improvement in “on” time without dyskinesia was superior in asleep DBS (+6.4 ± 3.0 h/d vs +1.7 ± 1.2 h/d, p = 0.002). Quality of life scores improved in both groups (+18.8 ± 9.4 in awake, +8.9 ± 11.5 in asleep). Improvement in summary index (p = 0.004) and subscores for cognition (p = 0.011) and communication (p < 0.001) were superior in asleep DBS. Speech outcomes were superior in asleep DBS, both in category (+2.77 ± 4.3 points vs −6.31 ± 9.7 points (p = 0.0012) and phonemic fluency (+1.0 ± 8.2 points vs −5.5 ± 9.6 points, p = 0.038). Conclusions: Asleep DBS for PD improved motor outcomes over 6 months on par with or better than awake DBS, was superior with regard to speech fluency and quality of life, and should be an option considered for all patients who are candidates for this treatment. Clinicaltrials.gov identifier: NCT01703598. Classification of evidence: This study provides Class III evidence that for patients with PD undergoing DBS, asleep intraoperative CT imaging–guided implantation is not significantly different from awake microelectrode recording–guided implantation in improving motor outcomes at 6 months.

[1]  P. Starr,et al.  An unexpectedly high rate of revisions and removals in deep brain stimulation surgery: Analysis of multiple databases. , 2016, Parkinsonism & related disorders.

[2]  A. Angwin,et al.  Speech outcomes in Parkinson's disease after subthalamic nucleus deep brain stimulation: A systematic review. , 2016, Parkinsonism & related disorders.

[3]  K. Kieburtz,et al.  A randomized trial of inhaled levodopa (CVT‐301) for motor fluctuations in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[4]  S. McCartney,et al.  Cost analysis of awake versus asleep deep brain stimulation: a single academic health center experience. , 2016, Journal of neurosurgery.

[5]  A. Tröster,et al.  Parkinson's disease outcomes after intraoperative CT-guided "asleep" deep brain stimulation in the globus pallidus internus. , 2016, Journal of neurosurgery.

[6]  L. Verhagen Metman,et al.  Gastroretentive carbidopa/levodopa, DM‐1992, for the treatment of advanced Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[7]  K. Kieburtz,et al.  Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study , 2014, The Lancet Neurology.

[8]  Albert Lee,et al.  Accuracy of deep brain stimulation electrode placement using intraoperative computed tomography without microelectrode recording. , 2013, Journal of neurosurgery.

[9]  M. Stacy,et al.  Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial , 2013, The Lancet Neurology.

[10]  Ron Alterman,et al.  Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial , 2012, The Lancet Neurology.

[11]  Thomas Foltynie,et al.  Reducing hemorrhagic complications in functional neurosurgery: a large case series and systematic literature review. , 2012, Journal of neurosurgery.

[12]  S. McClelland,et al.  A cost analysis of intraoperative microelectrode recording during subthalamic stimulation for Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[13]  B. Ravina,et al.  Risk of surgical delivery to deep nuclei: A meta‐analysis , 2011, Movement disorders : official journal of the Movement Disorder Society.

[14]  Grant D. Huang,et al.  Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. , 2009, JAMA.

[15]  L. Metman,et al.  Deep brain stimulation for Parkinson's disease: Prevalence of adverse events and need for standardized reporting , 2008, Movement disorders : official journal of the Movement Disorder Society.

[16]  G. Deuschl,et al.  Subthalamic nucleus deep brain stimulation: Summary and meta‐analysis of outcomes , 2006, Movement disorders : official journal of the Movement Disorder Society.

[17]  Gordon H Baltuch,et al.  Deep brain stimulation for movement disorders: morbidity and mortality in 109 patients. , 2003, Journal of neurosurgery.

[18]  P. Starr,et al.  Implantation of deep brain stimulators into the subthalamic nucleus: technical approach and magnetic resonance imaging-verified lead locations. , 2002, Journal of neurosurgery.

[19]  Aviva Abosch,et al.  Long-term Hardware-related Complications of Deep Brain Stimulation , 2002, Neurosurgery.

[20]  A. Lozano,et al.  Microelectrode Recordings in Movement Disorder Surgery , 2000 .